[Use of mitomycin C for corneal-conjunctival intraepithelial neoplasia: management options--case reports].
Three cases of corneal-conjunctival intraepithelial neoplasia treated differently with mitomycin C based on clinical presentation are reported. The selected patients were followed at the Department of Ophthalmology of the Casa de Saúde Santo Inácio. According to the clinical appearance of the lesions, 0.04% mitomycin C was employed in three different ways: 1) postoperative chemoablation; 2) preoperative chemoreduction; and 3) isolated chemoablation. Regression of the neoplastic lesion was observed in all cases with no recurrence detected during a follow-up time ranging from 18 to 29 months. Conjunctival hyperemia was the single side effect. The use of mitomycin C seems to be efficient and safe for the treatment of corneal-conjunctival intraepithelial neoplasia under several approaches.
de Figueirêdo
Régis Santana
RS
Faculdade de Medicina de Juazeiro do Norte, Rua Conceição 513, Centro, CEP 63010-220 Juazeiro do Norte, CE, Brazil. santana@netcariri.com.br
de Figueirêdo
Eugênio Santana
ES
D000287:Administration, Topical; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000601:surgery; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003316:Corneal Diseases / Q000188:drug therapy* / Q000601:surgery; D005134:Eye Neoplasms / Q000188:drug therapy / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin